Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Enovis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Enovis şirketinin toplam hissedar öz sermayesi $3.3B ve toplam borcu $1.3B olup, bu da borç-öz sermaye oranını 40.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.4B ve $2.2B dir.

Anahtar bilgiler

40.9%

Borç/özkaynak oranı

US$1.34b

Borç

Faiz karşılama oranı	n/a
Nakit	US$35.00m
Eşitlik	US$3.29b
Toplam yükümlülükler	US$2.15b
Toplam varlıklar	US$5.44b

Son finansal sağlık güncellemeleri

Recent updates

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Sep 24

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Aug 20

Enovis Languishing Despite Respectable Performance

Jul 15

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Jun 07

Enovis: Solid Growth, But Unstable Financial Footing

May 05

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Apr 22

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Feb 12

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Jan 14

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Dec 18

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Nov 05

Enovis Making Good Choices, But Not Seeing The Rewards

Sep 27

Is Enovis (NYSE:ENOV) A Risky Investment?

Sep 22

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Aug 03

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Jul 18

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Jun 20

Enovis Corporation Q4 2022 Earnings Preview

Feb 22

Is Enovis (NYSE:ENOV) A Risky Investment?

Feb 22

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Jan 25

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Nov 02

Is Enovis (NYSE:ENOV) A Risky Investment?

Oct 19

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?

Sep 14

Enovis launches augmented reality system ARVIS for use in hip, knee surgery

Jul 19

Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly

Jul 05

Enovis announces CFO transition

Jun 30

Enovis: Medtech Leftover Of Colfax With Some To Prove

May 23

As The Colfax Chapter Ends, Both ESAB And Enovis Have Something To Prove

Apr 05

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ENOV 'nin kısa vadeli varlıkları ( $1.2B ) kısa vadeli yükümlülüklerini ( $518.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: ENOV 'un kısa vadeli varlıkları ( $1.2B ) uzun vadeli yükümlülüklerini ( $1.6B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ENOV 'nin net borç/öz sermaye oranı ( 39.8% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: ENOV 'nin borç/öz sermaye oranı son 5 yılda 126.5% seviyesinden 40.9% seviyesine düştü.

Borç Kapsamı: ENOV 'nin borcu işletme nakit akışı ( 5.3% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: ENOV şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Enovis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Is Enovis (NYSE:ENOV) A Risky Investment?

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Is Enovis (NYSE:ENOV) A Risky Investment?

Recent updates

Price target decreased by 7.1% to US$67.00

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

Consensus EPS estimates fall by 20%

Second quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Languishing Despite Respectable Performance

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis: Solid Growth, But Unstable Financial Footing

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Price target increased by 8.6% to US$75.20

Full year 2023 earnings: EPS exceeds analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2024

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Enovis Corporation Announces Leadership Transition Plan

Consensus EPS estimates fall by 87%

No longer forecast to breakeven

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Making Good Choices, But Not Seeing The Rewards

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Is Enovis (NYSE:ENOV) A Risky Investment?

New major risk - Revenue and earnings growth

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Price target increased by 8.0% to US$68.17

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Independent Director notifies of intention to sell stock

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS misses analyst expectations

Enovis Corporation Q4 2022 Earnings Preview

Is Enovis (NYSE:ENOV) A Risky Investment?

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Is Enovis (NYSE:ENOV) A Risky Investment?

Now 21% undervalued after recent price drop

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?

Price target decreased to US$67.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis launches augmented reality system ARVIS for use in hip, knee surgery